1) U.S. Department of Health and Human Services, Food and Drug Administration:Guidance for Industry, Pharmacogenomic Data Submissions. US, 2005
2) 厚生労働省医薬食品局:薬品の臨床試験におけるファーマコゲノミクスの利用指針の作成に係る行政機関への情報の提供等について.薬食審査発第0318001号,2005
3) http://www.imm.ki.se/CYPalleles/default.htm
4) 平塚真弘:薬剤反応性に影響を及ぼす遺伝子多型の簡易迅速検査法の開発とその臨床応用.YAKUGAKU ZASSHI 122:451-463,2002
infection and peptic ulcer. Ann Intern Med 129:1027-1030, 1998
. Aliment Pharmacol Ther 25:1105-1113, 2007
7) Phillips K, Veenstra D, Oren E, et al:Potential role of pharmacogenomics in reducing adverse drug reactions. JAMA 286:2270-2279, 2001
8) Ingelman-Sundberg M, Oscarson M, McLellan RA:Polymorphic human cytochrome P450 enzymes:an opportunity for individualized drug treatment. Trends Pharmacol Sci 20:342-349, 1999
9) http://www.fda.gov/bbs/topics/NEWS/2005/NEW01190.html
10) Goetz PM, Knox KS, Suman JV, et al:The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 101:113-121, 2007
11) Jin Y, Desta Z, Stearns V, et al:CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97:30-39, 2005
12) Fisher B, Costantino JP, Wickerham DL, et al:Tamoxifen for the prevention of breast cancer:current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97:1652-1662, 2005
13) Kaniwa N, Kurose, Jinno H, et al:Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C>T(P229L)found in an African-American. Drug Metab Dispos 33:458-465, 2005